CytoMed Completes Dose Level 1 in Phase 1 Trial of CTM-N2D in Solid, Blood Cancers

MT Newswires Live

Jul 21

CytoMed Therapeutics (GDTC) said Monday that it has completed the dose level 1 portion of its phase 1 dose escalation trial of CTM-N2D to potentially treat advanced solid and blood cancers.

The company said it is scheduled to begin dose level 2 in Q3.

The trial aims to evaluate the safety and tolerability of CTM-N2D, a cell-based allogeneic therapy that can be given to patients without requiring compatibility matching tests, according to CytoMed.

Shares of CytoMed were up more than 1% in recent trading Monday.

Price: 2.05, Change: +0.03, Percent Change: +1.42

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2553340811"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553340811\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553340811?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-21 23:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553340811","market":"us","top_or_hot":-1,"title":"CytoMed Completes Dose Level 1 in Phase 1 Trial of CTM-N2D in Solid, Blood Cancers","media":"MT Newswires Live","content":"<html><body><p> CytoMed <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (GDTC) said Monday that it has completed the dose level 1 portion of its phase 1 dose escalation trial of CTM-N2D to potentially treat advanced solid and blood cancers.</p><p>The company said it is scheduled to begin dose level 2 in Q3.</p><p>The trial aims to evaluate the safety and tolerability of CTM-N2D, a cell-based allogeneic therapy that can be given to patients without requiring compatibility matching tests, according to CytoMed.</p><p>Shares of CytoMed were up more than 1% in recent trading Monday.</p><p>Price: 2.05, Change: +0.03, Percent Change: +1.42</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CytoMed Completes Dose Level 1 in Phase 1 Trial of CTM-N2D in Solid, Blood Cancers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytoMed Completes Dose Level 1 in Phase 1 Trial of CTM-N2D in Solid, Blood Cancers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-07-21 23:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CytoMed <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (GDTC) said Monday that it has completed the dose level 1 portion of its phase 1 dose escalation trial of CTM-N2D to potentially treat advanced solid and blood cancers.</p><p>The company said it is scheduled to begin dose level 2 in Q3.</p><p>The trial aims to evaluate the safety and tolerability of CTM-N2D, a cell-based allogeneic therapy that can be given to patients without requiring compatibility matching tests, according to CytoMed.</p><p>Shares of CytoMed were up more than 1% in recent trading Monday.</p><p>Price: 2.05, Change: +0.03, Percent Change: +1.42</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2553340811","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553340811","pubTimestamp":1753110630,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CytoMed Therapeutics  said Monday that it has completed the dose level 1 portion of its phase 1 dose escalation trial of CTM-N2D to potentially treat advanced solid and blood cancers.The company said it is scheduled to begin dose level 2 in Q3.The trial aims to evaluate the safety and tolerability of CTM-N2D, a cell-based allogeneic therapy that can be given to patients without requiring compatibility matching tests, according to CytoMed.Shares of CytoMed were up more than 1% in recent trading Monday.Price: 2.05, Change: +0.03, Percent Change: +1.42","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GDTC":"CytoMed Therapeutics Limited","BK4134":"信息科技咨询与其它服务","CTM":"Castellum, Inc."},"translate_title":"CytoMed完成CTM-N2D治疗实体癌、血癌的1期试验1剂量水平","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTM":1,"GDTC":0.9},"content_text":"CytoMed Therapeutics (GDTC) said Monday that it has completed the dose level 1 portion of its phase 1 dose escalation trial of CTM-N2D to potentially treat advanced solid and blood cancers.The company said it is scheduled to begin dose level 2 in Q3.The trial aims to evaluate the safety and tolerability of CTM-N2D, a cell-based allogeneic therapy that can be given to patients without requiring compatibility matching tests, according to CytoMed.Shares of CytoMed were up more than 1% in recent trading Monday.Price: 2.05, Change: +0.03, Percent Change: +1.42","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}